Voxelotor Improves Sickle Cell Disease of 83% of Adolescents in Phase 2a Trial
The sickle disease of 83 percent of adolescents improved after 16 weeks of taking Global Blood Therapeutics‘ voxelotor, preliminary results of a Phase 2a clinical trial indicate. Another important finding ... Read more